CN101278937A - Clear eye lotion containing latanoprost as effective ingredient - Google Patents

Clear eye lotion containing latanoprost as effective ingredient Download PDF

Info

Publication number
CN101278937A
CN101278937A CNA2008100902128A CN200810090212A CN101278937A CN 101278937 A CN101278937 A CN 101278937A CN A2008100902128 A CNA2008100902128 A CN A2008100902128A CN 200810090212 A CN200810090212 A CN 200810090212A CN 101278937 A CN101278937 A CN 101278937A
Authority
CN
China
Prior art keywords
latanoprost
bak
concentration
preparation
eye drop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2008100902128A
Other languages
Chinese (zh)
Other versions
CN101278937B (en
Inventor
浅田博之
木村章男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of CN101278937A publication Critical patent/CN101278937A/en
Application granted granted Critical
Publication of CN101278937B publication Critical patent/CN101278937B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

An object of the present invention is to provide better formulations of a latanoprost ophthalmic solution. The present invention provides a clear ophthalmic solution comprising latanoprost as an active ingredient and benzalkonium chloride as a preservative wherein white turbidity due to a change of formulation is prevented by adding non-ionic tonicity agent.

Description

The clear and bright eye drop that contains effective composition latanoprost
The application is to be JIUYUE in 2003 8 days, application number the dividing an application for the application of " the clear and bright eye drop that contains effective composition latanoprost " that be 03823948.5 (international application no is PCT/JP2003/011402), denomination of invention the applying date.
Technical field
The present invention relates to a kind of clear and bright and stable eye drop that contains treatment glaucoma medicine latanoprost as effective ingredient.
Background technology
Latanoprost is a kind of with chemistry isopropyl (Z) by name-7[(1R, 2R, 3R, 5S) 3,5-dihydroxy-2-[(3R)-3-hydroxyl-penta phenyl] cyclopenta] the 5-enanthic acid is the glaucomatous prostaglandin type of the treatment medicine of representative.Latanoprost is a kind of optionally FP receptor stimulating agent and reduces intraocular pressure (referring to, Japan Patent No.2721414 for example) by the outflow that promotes aqueous body fluid.The route of administration of latanoprost is an eye drip, and in the commercial eye drop (trade name: the smooth eye drop of hila) that obtains to contain latanoprost 0.005%.
One object of the present invention is to provide a kind of latanoprost eye drop better preparation.
As the antiseptic of eye drop, benzalkonium chloride (being abbreviated as " BAK " hereinafter) is most widely used general from the angle of effect and its similar (purposes).Yet although BAK has good antisepsis, BAK can cause disorder of cornea when it is used with high concentration.Therefore, when BAK joins eye drop, then wish to reduce as much as possible its concentration.
BAK described in the description refers to contain [C 6H 5CH 2N (CH 3) 2R] the compound product of the represented chemical constitution of Cl, wherein alkyl (representing with R) is C 8H 12-C 18H 37
BAK is defined as follows in Japan in the US and European pharmacopeia:
Pharmacopeia of Japan: BAK is by [C 6H 5CH 2N (CH 3) 2R] Cl represents that wherein R is meant C 8H 12-C 18H 37And mainly comprise C 12H 25And C 14H 29
American Pharmacopeia: BAK is a kind of by [C 6H 5CH 2N (CH 3) 2R] the alkyl benzyl dimethyl ammonium chloride mixture represented of Cl.Wherein R be all or some than C 8H 17High-grade alkyl functional group's mixture also mainly comprises C 12H 25, C 14H 29And C 16H 33
European Pharmacopoeia: BAK is a kind of mixture of alkyl benzyl dimethyl ammonium chloride, and wherein alkyl has C 8To C 18Chain length.
On the other hand, add usually isotonic agent in the eye drop to keep isotonicity and to be example with the alkali metal salt example of inorganic salt such as sodium chloride with as the alkali salt of magnesium chloride.
Further, add usually buffer in the eye drop preventing the variation of pH, and with as the inorganic salt of sodium phosphate, sodium borate with as sodium acetate, the organic salt of sodium citrate and sodium carbonate is example.
All comprise isotonic agent and buffer agent in the commercially available latanoprost eye drop.
The present invention prepares and has studied the latanoprost eye drop of the additive that contains these extensive uses.
As a result, astoundingly it be proved to be 0.015% or the BAK of higher concentration in do not find white casse, but 0.01% or the BAK of lower concentration in discovery is arranged.That is because hydrophobic latanoprost and BAK have formed a kind of complex, and simultaneously because the salt caused salting out of additive for example, latanoprost-BAK complex is precipitated.The present invention has disclosed should the fact, beat allly is, is low to moderate 0.01% or this complex precipitation not when lower up to BAK concentration.Though commercially available latanoprost eye drop (trade name: the smooth eye drop of hila) contain 0.02% BAK, do not produce the problem of white casse.Yet as mentioned above, although BAK is a kind of good antiseptic, it can cause disorder of cornea when using with high concentration.Therefore, when BAK joins in the eye drop, then wish to reduce as much as possible its concentration.
Detailed Description Of The Invention
At first research prevents the various additives of white casse, and the inventor finds and can prevent white casse by adding surfactant.
Find that by the further investigation that the kind of being absorbed in BAK is finished the mixing cpd that can not adopt the above-mentioned chemical constitution form that contains 8 to 18 carbon atom alkyls to represent occurs but the BAK that adopts alkyl to contain 12 carbon atoms can prevent white casse.
Further, the present invention considers that the use of salt such as isotonic agent can cause white casse and is absorbed in this isotonic agent and finishes accurate research.As a result, find to adopt the nonionic isotonic agent can prevent white casse as isotonic agent.
That is, found to obtain to contain the clear and bright eye drop of effective composition latanoprost and antiseptic benzalkonium chloride, wherein adopted at least aly to be selected from following 1) to 3) method prevent to change the white casse that causes by preparation;
1) add surfactant,
2) adopt by formula [C 6H 5CH 2N (CH 3) 2R] benzalkonium chloride of Cl (wherein R is the alkyl that contains 12 carbon atoms) expression do antiseptic and
3) add the nonionic isotonic agent as isotonic agent.
Above-mentioned three kinds of modes can separately or be share.
Preferred 0.001 to 0.01% (W/V) of the concentration of the effective ingredient latanoprost of eye drop of the present invention, especially preferred 0.005% (W/V).
First method of the present invention is to add surfactant.When adding surfactant, can not rely on the isotonic agent and the BAK that are adopted, prevent the clear and bright latanoprost eye drop of white casse.
The example of surfactant is a polyoxyethylene sorbitan monoleate, polyoxyethylene hydrogenated Oleum Ricini 60, polyoxy 35 Oleum Ricini, the polyglycol monostearate ester, macrogol (macrogol) 4000, lecithin, sucrose ester, polyoxyethylene alkyl ether, the polyoxy stearate, polyoxyethylene polyoxypropylene glycol and analog thereof, preferred polyoxyethylene sorbitan monoleate, polyoxyethylene hydrogenated Oleum Ricini 60, polyoxy 35 Oleum Ricini.Surfactant concentrations preferred 0.001 to 0.5%.
Second method of the present invention is to adopt [C 6H 5CH 2N (CH 3) 2R] benzalkonium chloride of Cl (wherein R is the alkyl that contains 12 carbon atoms) structural formula representative makes antiseptic.(be abbreviated as " BAK-C hereinafter at the benzalkonium chloride that contains 12 carbon atoms described in the description 12") refer to from [C 6H 5CH 2N (CH 3) 2R] benzalkonium chloride represented of Cl chemical structural formula, and its alkyl (representing with R in the structural formula) is C 12H 25
Adopt BAK-C 12Make antiseptic and can not rely on the isotonic agent that is adopted, prevent the clear and bright latanoprost eye drop of white casse.
Adopt commercially available BAK-C 12BAK-C 12Preferred 0.01% (W/V) of concentration or lower.Cross when low when BAK concentration, can not show enough antisepsises.Therefore, preferred BAK concentration is in the scope of 0.003 to 0.01 (W/V).
The third method of the present invention is to add the nonionic isotonic agent as isotonic agent.Adopt the nonionic isotonic agent can not rely on the BAK that is adopted, prevent the clear and bright latanoprost eye drop of white casse.When using the nonionic isotonic agent, can reduce the total amount of salt in the eye drop.As a result, the influence of salting out reduces, and prevents white casse by this.
The nonionic isotonic agent can be any material that is generally used for eye drop, and especially with glycerol, mannitol, Polyethylene Glycol, propylene glycol, trehalose, sucrose and analog thereof.The concentration of nonionic isotonic agent can be adjusted to every kind of material can isoosmotic concentration.
By adding a kind of pH buffer, a kind of pH regulator agent, a kind of solubilizing agent or a kind of viscosifier can at random prepare eye drop of the present invention.The example of PH buffer is as sodium phosphate, sodium dihydrogen phosphate, sodium hydrogen phosphate, potassium phosphate, the phosphate of potassium dihydrogen phosphate and dipotassium hydrogen phosphate; As the borate of sodium borate and potassium borate, as the sal limonis of sodium citrate and disodium citrate with as the carbonate of sodium carbonate and sodium bicarbonate.The example of PH regulator is a hydrochloric acid, citric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide and analog thereof.The example of cosolvent is a polyoxyethylene sorbitan monoleate, polyoxyethylene hydrogenated Oleum Ricini 60, macrogol 4000 and analog thereof.The example of viscosifier is hydroxypropyl alkyl methyl celluloses, hydroxypropyl alkylcellulose, polyvinyl alcohol, carboxyl ethylene copolymer, polyvinylpyrrolidone and analog thereof.
In first and second kinds of methods, can add as sodium chloride, potassium chloride, the salt of calcium chloride or magnesium chloride is as isotonic agent.
Eye drop pH of the present invention preferably is adjusted to 3 to 8, and more preferably 4 to 7.
Eye drop of the present invention can adopt the prepared of extensive use.
Realize optimal mode of the present invention
Method 1) embodiment
Embodiment 1-1
Dissolving crystallized sodium dihydrogen phosphate (0.2g) in pure water (about 90ml), sodium chloride (0.8g), polyoxyethylene sorbitan monoleate (0.01g) and benzalkonium chloride (0.01g) are regulated pH to 6.7, and the adding pure water makes that cumulative volume is that 100ml produces a kind of carrier in solution.Carrier (100ml) joins latanoprost (5mg), and stirs the mixture when about 80 ℃ of heating in water bath latanoprost is dissolved in carrier.Solution temperature returns to room temperature, and determines that subsequently pH is 6.7.
Embodiment 1-2
Dissolving crystallized sodium dihydrogen phosphate (0.2g) in pure water (about 90ml), sodium chloride (0.8g), polyoxyethylene hydrogenated Oleum Ricini 60 (0.01g) and benzalkonium chloride (0.01g) are regulated pH to 6.7, and the adding pure water makes that cumulative volume is that 100ml produces a kind of carrier in solution.Carrier (100ml) joins latanoprost (5mg), and stirs the mixture when about 80 ℃ of heating in water bath latanoprost is dissolved in carrier.Solution temperature returns to room temperature, and determines that subsequently pH is 6.7.
Embodiment 1-3
Dissolving crystallized sodium dihydrogen phosphate (0.2g) in pure water (about 90ml), sodium chloride (0.8g), polyoxy 35 Oleum Ricini 60 (0.01g) and benzalkonium chloride (0.01g) are regulated pH to 6.7, and the adding pure water makes that cumulative volume is that 100ml produces a kind of carrier in solution.Carrier (100ml) joins latanoprost (5mg), and stirs the mixture when about 80 ℃ of heating in water bath latanoprost is dissolved in carrier.Solution temperature returns to room temperature, and determines that subsequently pH is 6.7.
Method 2) embodiment
Embodiment 2-1
Dissolving crystallized sodium dihydrogen phosphate (0.2g) in pure water (about 90ml), sodium chloride (0.8g), polyoxyethylene hydrogenated Oleum Ricini 60 (0.01g) and BAK-C 12(0.01g), regulate pH to 6.7, and the adding pure water makes that cumulative volume is that 100ml produces a kind of carrier in solution with the 1N sodium hydrate aqueous solution.Carrier (100ml) joins latanoprost (5mg), and stirs the mixture when about 80 ℃ of heating in water bath latanoprost is dissolved in carrier.Solution temperature returns to room temperature, and determines that subsequently pH is 6.7.
Embodiment 2-2
Dissolving crystallized sodium dihydrogen phosphate (0.2g) in pure water (about 90ml), sodium chloride (0.8g), and BAK-C 12(0.005g), regulate pH to 6.7, and the adding pure water makes that cumulative volume is that 100ml produces a kind of carrier in solution with the 1N sodium hydrate aqueous solution.Carrier (100ml) joins latanoprost (5mg), and stirs the mixture when about 80 ℃ of heating in water bath latanoprost is dissolved in carrier.Solution temperature returns to room temperature, and determines that subsequently pH is 6.7.
Method 3) embodiment
Embodiment 3-1
Dissolving crystallized sodium dihydrogen phosphate (0.2g) in pure water (about 90ml), thick glycerol (2.3g) and BAK (0.01g) regulate pH to 6.7 with the 1N sodium hydrate aqueous solution, and the adding pure water makes that cumulative volume is that 100ml produces a kind of carrier in solution.Carrier (100ml) joins latanoprost (5mg), and stirs the mixture when about 80 ℃ of heating in water bath latanoprost is dissolved in carrier.Solution temperature returns to room temperature, and determines that subsequently pH is 6.7.
Embodiment 3-2
Dissolving crystallized sodium dihydrogen phosphate (0.2g) in pure water (about 90ml), mannitol (4.5g) and BAK (0.01g) regulate pH to 6.7 with the 1N sodium hydrate aqueous solution, and the adding pure water makes that cumulative volume is that 100ml produces a kind of carrier in solution.Carrier (100ml) joins latanoprost (5mg), and stirs the mixture when about 80 ℃ of heating in water bath latanoprost is dissolved in carrier.Solution temperature returns to room temperature, and determines that subsequently pH is 6.7.
Embodiment 3-3
Dissolving crystallized sodium dihydrogen phosphate (0.2g) in pure water (about 90ml), PEG400 (8.0g) and BAK (0.01g) regulate pH to 6.7 with the 1N sodium hydrate aqueous solution, and the adding pure water makes that cumulative volume is that 100ml produces a kind of carrier in solution.Carrier (100ml) joins latanoprost (5mg), and stirs the mixture when about 80 ℃ of heating in water bath latanoprost is dissolved in carrier.Solution temperature returns to room temperature, and determines that subsequently pH is 6.7.
Embodiment 3-4
Dissolving crystallized sodium dihydrogen phosphate (0.2g) in pure water (about 90ml), propylene glycol (2.0g) and BAK (0.01g) regulate pH to 6.7 with the 1N sodium hydrate aqueous solution, and the adding pure water makes that cumulative volume is that 100ml produces a kind of carrier in solution.Carrier (100ml) joins latanoprost (5mg), and stirs the mixture when about 80 ℃ of heating in water bath latanoprost is dissolved in carrier.Solution temperature returns to room temperature, and determines that subsequently pH is 6.7.
Embodiment 3-5
Dissolving crystallized sodium dihydrogen phosphate (0.2g) in pure water (about 90ml), trehalose (9.0g) and BAK (0.01g) regulate pH to 6.7 with the 1N sodium hydrate aqueous solution, and the adding pure water makes that cumulative volume is that 100ml produces a kind of carrier in solution.Carrier (100ml) joins latanoprost (5mg), and stirs the mixture when about 80 ℃ of heating in water bath latanoprost is dissolved in carrier.Solution temperature returns to room temperature, and determines that subsequently pH is 6.7.
Experiment 1:
The mensuration of latanoprost residual ratio and the observation of outward appearance
1) is prepared as follows Comparative formulation 1 to 4.
In the 100ml glass beaker, put into pure water (about 90ml).Dissolving crystallized sodium dihydrogen phosphate (0.2g) in pure water, sodium chloride (0.9g) is regulated pH to 6.7 with the 1N sodium hydrate aqueous solution, and the adding pure water makes that cumulative volume is that 100ml produces a kind of carrier in solution.Carrier (100ml) joins latanoprost (5mg), and stirs the mixture when about 80 ℃ of heating in water bath latanoprost is dissolved in carrier.Solution temperature returns to room temperature, and determines that subsequently pH is 6.7.Add water for injection in the solution adjusted volume to 100ml.The accurate latanoprost solution of putting into 10ml in teat glass wherein adds 50,100,100 or 1% the BAK solution (alkyl R contains the mixing cpd of 12,14 and 16 carbon atoms in above chemical structural formula) of 200 μ l, and with its mixing.These preparations are as shown in table 1.
2) be prepared as follows preparation 1 to 3.
In the 100ml glass beaker, put into pure water (about 90ml).Dissolving crystallized sodium dihydrogen phosphate (0.2g) in pure water, sodium chloride (0.9g) and various surfactant, its concentration separately is as shown in table 2.Regulate pH to 6.7 with sodium hydrate aqueous solution or dilute hydrochloric acid, and the adding pure water makes that cumulative volume is that 100ml produces a kind of carrier in solution.Carrier (100ml) joins latanoprost (5mg), and stirs the mixture when about 80 ℃ of heating in water bath latanoprost is dissolved in carrier.Solution temperature returns to room temperature, and determines that subsequently pH is 6.7.Add water for injection in the solution adjusted volume to 100ml.The accurate latanoprost solution of putting into 10ml in teat glass wherein adds 1% the BAK solution (alkyl R contains the mixing cpd of 12,14 and 16 carbon atoms in above chemical structural formula) of 100 μ l, and with its mixing.These preparations are as shown in table 2.
3) be prepared as follows preparation 4 and 5.
In the 100ml glass beaker, put into pure water (about 90ml).Dissolving crystallized sodium dihydrogen phosphate (0.2g) in pure water, sodium chloride (0.9g) is regulated pH to 6.7 with the 1N sodium hydrate aqueous solution, and the adding pure water makes that cumulative volume is that 100ml produces a kind of carrier in solution.Carrier (100ml) joins latanoprost (5mg), and stirs the mixture when about 80 ℃ of heating in water bath latanoprost is dissolved in carrier.Solution temperature returns to room temperature, and determines that subsequently pH is 6.7.Add water for injection in the solution adjusted volume to 100ml.The accurate latanoprost solution of putting into 10ml in teat glass wherein adds 1% the BAK-C of 50 or 100 μ l 12Solution, and with its mixing.These preparations are as shown in table 3.
4) be prepared as follows preparation 6 to 10.
In the 100ml glass beaker, put into pure water (about 90ml).Dissolving crystallized sodium dihydrogen phosphate (0.2g) and various nonionic isotonic agent are so that various concentration value as shown in table 4 in pure water, regulate pH to 6.7 with sodium hydrate aqueous solution or dilute hydrochloric acid, and the adding pure water makes that cumulative volume is that 100ml produces a kind of carrier in solution.Carrier (100ml) joins latanoprost (5mg), and stirs the mixture when about 80 ℃ of heating in water bath latanoprost is dissolved in carrier.Solution temperature returns to room temperature, and determines that subsequently pH is 6.7.Add water for injection in the solution adjusted volume to 100ml.The accurate latanoprost solution of putting into 10ml in teat glass wherein adds 1% the BAK solution (alkyl R contains the mixing cpd of 12,14 and 16 carbon atoms in above chemical structural formula) of 100 μ l, and with its mixing.These preparations are as shown in table 4.
5) observe outward appearance by every kind of solution of method for preparing, and in 25ml mixings flask every kind of solution of accurate extraction 1ml.Filter membrane with 0.22-μ m filters 9 milliliters of every kind of rest solution.
6) adopt high effective liquid chromatography for measuring to filter the concentration of latanoprost in the solution of front and back, and calculate residual ratio.
Table 1
Comparative formulation 1 Comparative formulation 2 Comparative formulation 3 Comparative formulation 4
Latanoprost 0.005 0.005 0.005 0.005
The crystallization sodium dihydrogen phosphate 0.2 0.2 0.2 0.2
Sodium chloride 0.9 0.9 0.9 0.9
BAK 0.02 0.015 0.01 0.005
Dilute hydrochloric acid q.s q.s q.s q.s
Sodium hydroxide q.s q.s q.s q.s
Pure water q.s q.s q.s q.s
(unit in the table: % (W/V), q.s: capacity)
Table 2
Preparation 1 Preparation 2 Preparation 3
Latanoprost 0.005 0.005 0.005
The crystallization sodium dihydrogen phosphate 0.2 0.2 0.2
Sodium chloride 0.9 0.9 0.9
BAK 0.01 0.01 0.01
Polyoxyethylene sorbitan monoleate 0.01 - -
Polyoxyethylene hydrogenated Oleum Ricini 60 - 0.01 -
Polyoxy 35 Oleum Ricini - - 0.01
Dilute hydrochloric acid q.s q.s q.s
Sodium hydroxide q.s q.s q.s
Pure water q.s q.s q.s
(unit in the table: % (W/V), q.s: capacity)
Table 3
Preparation 4 Preparation 5
Latanoprost 0.005 0.005
The crystallization sodium dihydrogen phosphate 0.2 0.2
Sodium chloride 0.9 0.9
BAK C 12 0.01 0.005
Dilute hydrochloric acid q.s q.s
Sodium hydroxide q.s q.s
Pure water q.s q.s
(unit in the table: % (W/V), q.s: capacity)
Table 4
Preparation 6 Preparation 7 Preparation 8 Preparation 9 Preparation 10
Latanoprost 0.005 0.005 0.005 0.005 0.005
The crystallization sodium dihydrogen phosphate 0.2 0.2 0.2 0.2 0.2
BAK 0.01 0.01 0.01 0.01 0.01
Thick glycerol 2.5
Mannitol 5
PEG400 8.5
Propylene glycol 2.1
Trehalose 9.25
Dilute hydrochloric acid q.s q.s q.s q.s q.s
Sodium hydroxide q.s q.s q.s q.s q.s
Pure water q.s q.s q.s q.s q.s
(unit in the table: % (W/V), q.s: capacity)
The result
The outward appearance observed result and the residual ratio of table 5 expression Comparative formulation 1 to 4 are measured.Contain 0.02% or the Comparative formulation 1 and 2 of 0.015%BAK join latanoprost, outward appearance is a water white transparency, and residual ratio is 96.8 to 99.4%.That is to say, preparation does not change.Yet, contain 0.01% or the Comparative formulation 3 and 4 of 0.005%BAK in observe white casse, and residual ratio reduces.That is to say, preparation changes.
The outward appearance observed result of table 6 expression preparation 1 to 3 (method 1) and residual ratio are measured.In Comparative formulation 3 and 4, observe white casse, and residual ratio reduces.On the contrary, contain in the preparation 1 to 3 of surfactant and do not find white casse, and residual ratio keeps high value, that is: 97.2 to 99.8%.These results show that surfactant prevents that preparation from changing, and obtains stable and clear and bright eye drop by this when adding surfactant in the preparation that contains latanoprost and BAK.
The outward appearance observed result of table 7 expression preparation 4 to 5 (method 2) and residual ratio are measured.Adopt the Comparative formulation 3 and 4 of BAK, find white casse, and residual ratio reduces.On the contrary, containing BAKC 12Substitute in the preparation 4 and 5 of BAK, do not find white casse, and residual ratio is 97.3 to 98.2%.That is to say, preparation does not change.These results show the BAKC that substitutes BAK when adding 12In the preparation that contains latanoprost, BAKC 12Prevent that preparation from changing, and obtain stable and clear and bright eye drop by this.
The outward appearance observed result and the residual ratio of table 8 expression preparation 6 to 10 are measured.Adopt the Comparative formulation 3 and 4 of sodium chloride, find white casse, and residual ratio reduces as isotonic agent.On the contrary, in the preparation 6 to 10 that contains the alternative sodium chloride of nonionic isotonic agent, do not find white casse, and residual ratio is 94.6 to 98.6%.That is to say, preparation does not change.These results show that this agent prevents that preparation from changing, and obtains stable and clear and bright eye drop by this when adding isotonic agent in the preparation that contains latanoprost and BAK.
Table 5
Comparative formulation 1 Comparative formulation 2 Comparative formulation 3 Comparative formulation 4
Outward appearance Water white transparency Water white transparency White casse White casse
Residual ratio (%) 99.4 96.8 67.3 83.5
Table 6
Preparation 1 Preparation 2 Preparation 3
Outward appearance Water white transparency Water white transparency Water white transparency
Residual ratio (%) 99.8 98.0 97.2
Table 7
Preparation 4 Preparation 5
Outward appearance Water white transparency Water white transparency
Residual ratio (%) 97.3 98.2
Table 8
Preparation 6 Preparation 7 Preparation 8 Preparation 9 Preparation 10
Outward appearance Water white transparency Water white transparency Water white transparency Water white transparency Water white transparency
Residual ratio (%) 98.6 96.0 94.6 98.2 96.2
Experiment 2: the antimicrobial detection of tiring
Correct the described antimicrobial of the version detection method of tiring according to Pharmacopeia of Japan the 13 and finish the foregoing description 1-1, the detection of tiring of the antimicrobial of 2-1 and 3-1.
Represent testing result in the table 9.Under the situation of antibacterial, in any embodiment, all do not detect antibacterial.Under the situation of fungus, not detecting the fungus that fungus or quantity inoculated at inoculation four stars after date has significant minimizing.Therefore, find to have showed enough antisepsises.
Table 9
Figure A20081009021200141
Industrial applicibility
Also can then can provide clear and bright Latanoprost eye drops by adding surfactant even reduce BAK concentration. In addition, by adopting BAKC12As anticorrisive agent, even reducing, BAK concentration also can provide clear and bright Latanoprost eye drops. Further, add the nonionic isotonic agent, also can provide clear and bright Latanoprost eye drops and BAK concentration even lower even BAK concentration reduces.

Claims (10)

1, contains the clear and bright eye drop of effective composition latanoprost and antiseptic benzalkonium chloride, it is characterized in that, prevent that by containing the nonionic isotonic agent preparation from changing the white casse that causes.
2, eye drop as claimed in claim 1 is characterized in that, benzalkonium chloride is by formula [C 6H 5CH 2N (CH 3) 2R] Cl represents that wherein R is the alkyl that contains 12 carbon atoms.
3, eye drop as claimed in claim 1 is characterized in that, the concentration of latanoprost is 0.001～0.01%W/V, and the concentration of benzalkonium chloride is 0.003～0.01%W/V.
4, eye drop as claimed in claim 1 is characterized in that, the concentration of latanoprost is 0.005%W/V, and the concentration of benzalkonium chloride is 0.003～0.01%W/V.
5, eye drop as claimed in claim 1 is characterized in that, the nonionic isotonic agent is a glycerol, mannitol, Polyethylene Glycol, propylene glycol, trehalose or sucrose.
6, prevent to contain the method that changes the white casse that causes in the eye drop of effective composition latanoprost and antiseptic benzalkonium chloride by preparation by adding the nonionic isotonic agent.
7, the method that prevents white casse as claimed in claim 6 is characterized in that, benzalkonium chloride is by formula [C 6H 5CH 2N (CH 3) 2R] Cl represents that wherein R is the alkyl that contains 12 carbon atoms.
8, the method that prevents white casse as claimed in claim 6 is characterized in that, the concentration of latanoprost is 0.001～0.01%W/V, and the concentration of benzalkonium chloride is 0.003～0.01%W/V.
9, the method that prevents white casse as claimed in claim 6 is characterized in that, the concentration of latanoprost is 0.005%W/V, and the concentration of benzalkonium chloride is 0.003 to 0.01%W/V.
10, the method that prevents white casse as claimed in claim 6 is characterized in that, the nonionic isotonic agent is a glycerol, mannitol, Polyethylene Glycol, propylene glycol, trehalose or sucrose.
CN2008100902128A 2002-09-09 2003-09-08 Clear eye lotion containing latanoprost as effective ingredient Expired - Fee Related CN101278937B (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP263030/2002 2002-09-09
JP263039/2002 2002-09-09
JP2002263039 2002-09-09
JP263035/2002 2002-09-09
JP2002263035 2002-09-09
JP2002263030 2002-09-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB038239485A Division CN100389770C (en) 2002-09-09 2003-09-08 Transparent eye drops containing latanoprost

Publications (2)

Publication Number Publication Date
CN101278937A true CN101278937A (en) 2008-10-08
CN101278937B CN101278937B (en) 2012-05-30

Family

ID=35306249

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2008100902113A Expired - Fee Related CN101278936B (en) 2002-09-09 2003-09-08 Clear eye lotion containing latanoprost as effective ingredient
CN2008100902128A Expired - Fee Related CN101278937B (en) 2002-09-09 2003-09-08 Clear eye lotion containing latanoprost as effective ingredient
CNB038239485A Expired - Fee Related CN100389770C (en) 2002-09-09 2003-09-08 Transparent eye drops containing latanoprost

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2008100902113A Expired - Fee Related CN101278936B (en) 2002-09-09 2003-09-08 Clear eye lotion containing latanoprost as effective ingredient

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB038239485A Expired - Fee Related CN100389770C (en) 2002-09-09 2003-09-08 Transparent eye drops containing latanoprost

Country Status (1)

Country Link
CN (3) CN101278936B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102028697B (en) * 2009-09-27 2014-01-08 上海信谊药厂有限公司 Non-ionic surface active agent-containing Latanoprost eye drop and preparation method thereof
CN102716074B (en) * 2012-06-28 2013-10-16 武汉武药科技有限公司 Bimatoprost eye drops and preparation method thereof
WO2014119643A1 (en) * 2013-01-31 2014-08-07 千寿製薬株式会社 Clear aqueous solution

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62277323A (en) * 1986-02-19 1987-12-02 Sankyo Co Ltd Production of eye drop containing ketotifen fumarate
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
AU7680096A (en) * 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop

Also Published As

Publication number Publication date
CN101278936A (en) 2008-10-08
CN101278937B (en) 2012-05-30
CN1688317A (en) 2005-10-26
CN101278936B (en) 2012-10-31
CN100389770C (en) 2008-05-28

Similar Documents

Publication Publication Date Title
JP5171606B2 (en) Clear ophthalmic solution containing latanoprost as an active ingredient
CN102481301A (en) Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin
AU738413B2 (en) Human growth hormone-containing aqueous pharmaceutical composition
JPH07116029B2 (en) Tranilast aqueous solution formulation
CN102014920B (en) Eye-drop preparation and use thereof
ES2393675T3 (en) Preservative composition for ophthalmic use
KR101027454B1 (en) Stable eye drops containing latanoprost as the active ingredient
CN101278936B (en) Clear eye lotion containing latanoprost as effective ingredient
JP2939082B2 (en) Stable vitamin A palmitate and vitamin E solubilized eye drops
JP2005263792A (en) Clear latanoprost eye lotion
JP5237137B2 (en) Ophthalmic agent
JP2004123729A (en) Clear eye lotion containing latanoprost as effective ingredient
JPH0129170B2 (en)
JP2000191534A (en) Water-soluble ophthalmic solution
US8785497B2 (en) Aqueous ophthalmic compositions containing anionic therapeutic agents
CA2076558A1 (en) Pharmaceutical compositions containing bradykinin antagonists for local use on the nose and eyes
JP2009256281A (en) Isopropyl unoprostone containing ophthalmic preparation formulation
JP2010132587A (en) Ophthalmic agent
JPH06700B2 (en) Stable aqueous solution
WO2005079809A1 (en) Transparent latanoprost eye drops

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120530

Termination date: 20180908

CF01 Termination of patent right due to non-payment of annual fee